Aktis Oncology, a Phase 1 biotech developing targeted radiopharmaceuticals to treat solid tumors, raised $318 million by offering 17.7 million shares at $18, the high end of the range of $16 to $18. The company originally planned to offer 11.8 million shares at ...read more
Cantor Equity Partners VI, the fifteenth blank check company formed by Cantor Fitzgerald, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. The company plans to raise $100 million by offering 10 million shares at $10....read more
Bleichroeder Acquisition II, a blank check company led by investment veterans targeting technology, raised $250 million by offering 25 million units at $10.00. Each unit consists of one share of common stock and one-third of one warrant, exercisable at $11.50. ...read more
Phase 1 solid tumor biotech Aktis Oncology prices IPO at $18, the high end of the range
Aktis Oncology, a Phase 1 biotech developing targeted radiopharmaceuticals to treat solid tumors, raised $318 million by offering 17.7 million shares at $18, the high end of the range of $16 to $18. The company originally planned to offer 11.8 million shares at ...read more
SPAC Cantor Equity Partners VI files for a $100 million IPO
Cantor Equity Partners VI, the fifteenth blank check company formed by Cantor Fitzgerald, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. The company plans to raise $100 million by offering 10 million shares at $10....read more
SPAC Bleichroeder Acquisition II prices $250 million IPO, targeting technology
Bleichroeder Acquisition II, a blank check company led by investment veterans targeting technology, raised $250 million by offering 25 million units at $10.00. Each unit consists of one share of common stock and one-third of one warrant, exercisable at $11.50. ...read more